About BioCorteX
BioCorteX is a company based in London (United Kingdom) founded in 2021 by Nik Sharma and Muhannad Alomari. BioCorteX has raised $5 million across 2 funding rounds from investors including Sofinnova Partners and Hoxton Ventures. BioCorteX offers products and services including Carbon Knowledge and Carbon Mirror. BioCorteX operates in a competitive market with competitors including Biogen, Denali Therapeutics, Kriya Therapeutics, Annexon and Entrada Therapeutics, among others.
- Headquarter London, United Kingdom
- Founders Nik Sharma, Muhannad Alomari
- SectorsHealthcare
- Email••••••••
- Website biocortex.com
- Social LinkedIn X Facebook
- Legal Name Biocortex Ltd
- Date of Incorporation 23 Mar, 2021
- Jurisdiction LONDON, ENGLAND
- Total Equity Funding$5M (USD)
in 2 rounds
- Latest Funding Round$5M (USD), Seed
Mar 2023
- InvestorsSofinnova Partners
& 1 more
Products & Services of BioCorteX
BioCorteX offers a comprehensive portfolio of products and services, including Carbon Knowledge and Carbon Mirror.
Database of global microbiome samples for drug discovery insights.
Simulates bacteria-drug interactions for therapeutic development.
Funding Insights of BioCorteX
BioCorteX has successfully raised a total of $5M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $5 million completed in March 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5M
- Total Rounds 2
- Last Round Seed — $5M
- Investors Count 2
All 2 funding rounds of BioCorteX with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2023 | $5M | Seed | – | Sofinnova Partners, Hoxton Ventures | – |
| Jan 2022 | – | Seed | – | – |
2 investors in total: 2 institutional.
Investors in BioCorteX
BioCorteX has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Sofinnova Partners and Hoxton Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Sofinnova Partners is focused on life sciences and healthcare investments. | – | sofinnovapartners.com | Paris, France | |
VC and PE firm focused on seed and early stage tech companies | – | hoxtonventures.com | London, United Kingdom |
Investor details for BioCorteX
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BioCorteX
2 people are tracked at BioCorteX (2 in leadership).
| Name | Role | Group |
|---|---|---|
Nik Sharma | Co-Founder & CEO | Leadership |
Muhannad Alomari | Co-Founder | Leadership |
Complete people profiles for BioCorteX
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of BioCorteX
3 dated milestones of BioCorteX across 2 years, from founding to its latest funding, stage changes and deals.
- Founded BioCorteX is founded.
- Funding First funding round.
- Funding Latest funding round, Seed, of $5.0M.
Competitors of BioCorteX
BioCorteX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Kriya Therapeutics, Annexon and Entrada Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| entradatx.com | 2016 | Boston, United States | $175.25M | 122 | Biologics platform developed for intracellular delivery in rare diseases. | |
| adamaspharma.com | 2002 | Emeryville, United States | $68.03M | 142 | Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics. | |
| sonomabio.com | 2012 | San Francisco, United States | $335M | 74 | T-cell-based therapies for autoimmune and degenerative diseases are developed. | |
| evelobio.com | 2015 | Cambridge, United States | $166.5M | 117 | Therapeutics for inflammatory diseases, COVID-19, and cancer are developed. | |
| juvlabs.com | 2017 | Dublin, Ireland | $289.89M | – | Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health | |
| alector.com | 2013 | San Francisco, United States | $214.78M | 211 | Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. |
Detailed competitors of BioCorteX
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biocortex
Complete news archive for BioCorteX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to BioCorteX
10 companies that operate in the same segment as BioCorteX (Microbiome Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Biosolutions and enzymes are developed for biotechnology applications across industries. | 2000 | Bags Sword, Denmark | – | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Gut microbiome insights, analytics, tests, and therapeutics are provided. | 2019 | Singapore, Singapore | USD 10.5 M | USD 1.37 M | – | |
Microbiome-based therapeutics for skin conditions like eczema are developed. | 2014 | Farmington, United States | USD 37.4 M | – | 12 | |
Engineered microbes are developed as programmable therapeutics for metabolic disorders. | 2013 | Cambridge, Massachusetts, United States | USD 34.4 M | USD 8 K | 1 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
Microbiome-based therapeutics for gut diseases are developed. | 2017 | Edinburgh, Scotland, United Kingdom | USD 72.96 M | – | 65 | |
The gut-brain axis is explored for therapeutic and nutritional innovations. | 2014 | New York, New York, United States | USD 479 M | – | 84 | |
Microbiome therapeutics are developed to address diverse diseases. | 2010 | Cambridge, Massachusetts, United States | USD 257.13 M | USD 789 K | 103 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about BioCorteX
BioCorteX was founded in 2021 and raised its 1st funding round 1 year after it was founded.
BioCorteX is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Nik Sharma is the current CEO of BioCorteX. They have also founded this company.
BioCorteX is a funded company, having raised a total of $5M across 2 funding rounds to date.
BioCorteX was founded in 2021 in London, United Kingdom, within the biotechnology sector. A human-microbiome platform is utilized to advance drug development through deep technology that explores interactions between therapeutics and bacteria, viruses, and fungi. The carbon mirror platform, a computational simulation tool, is employed to model drug-bacteria dynamics from first principles. Operations focus on leveraging microbiome synergies for health applications.
BioCorteX's top competitors include Alector, Entrada Therapeutics and Annexon.
BioCorteX offers Carbon Knowledge and Carbon Mirror.
BioCorteX has 2 investors. Key investors include Sofinnova Partners, and Hoxton Ventures.
BioCorteX operates through Biocortex Ltd.